Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carbidopa + levodopa (Amneal Pharmaceuticals, Inc.)
- Development stage
- Approved
- Lead developer
- Amneal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rytary is an oral extended-release capsule formulation of carbidopa and levodopa designed to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. Developed by Impax Laboratories (now Amneal Pharmaceuticals), Rytary utilizes a specialized bead-based delivery system containing both immediate-release and polymer-coated extended-release beads in a 1:4 ratio of carbidopa to levodopa. This design aims to provide rapid onset of action while maintaining therapeutic plasma concentrations for a longer duration compared to immediate-release formulations, thereby reducing "off" time in patients with fluctuating motor symptoms. Levodopa serves as a precursor to dopamine, crossing the blood-brain barrier to replenish depleted striatal dopamine, while carbidopa acts as a peripheral decarboxylase inhibitor, preventing the premature conversion of levodopa to dopamine in the systemic circulation and reducing peripheral side effects.
- Brand names
- Rytary
- Other names
- carbidopa/levodopa extended-release capsules
02
Targets
DDC (Aromatic L-amino acid decarboxylase)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on carbidopa + levodopa (Amneal Pharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carbidopa + levodopa (Amneal Pharmaceuticals, Inc.).